JP2010509331A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509331A5 JP2010509331A5 JP2009536282A JP2009536282A JP2010509331A5 JP 2010509331 A5 JP2010509331 A5 JP 2010509331A5 JP 2009536282 A JP2009536282 A JP 2009536282A JP 2009536282 A JP2009536282 A JP 2009536282A JP 2010509331 A5 JP2010509331 A5 JP 2010509331A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- effective amount
- taxane
- vegf antibody
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940123237 Taxane Drugs 0.000 claims description 47
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 45
- 239000002105 nanoparticle Substances 0.000 claims description 34
- 206010027476 Metastases Diseases 0.000 claims description 22
- 230000009401 metastasis Effects 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 102000014914 Carrier Proteins Human genes 0.000 claims description 13
- 108010078791 Carrier Proteins Proteins 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000002062 proliferating effect Effects 0.000 claims description 8
- 102000009027 Albumins Human genes 0.000 claims description 7
- 108010088751 Albumins Proteins 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 229960000397 bevacizumab Drugs 0.000 claims description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 43
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/594,417 | 2006-11-06 | ||
| US11/594,417 US20070166388A1 (en) | 2005-02-18 | 2006-11-06 | Combinations and modes of administration of therapeutic agents and combination therapy |
| PCT/US2007/023446 WO2008057562A1 (en) | 2006-11-06 | 2007-11-06 | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013230872A Division JP2014043454A (ja) | 2006-11-06 | 2013-11-07 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010509331A JP2010509331A (ja) | 2010-03-25 |
| JP2010509331A5 true JP2010509331A5 (enExample) | 2011-12-15 |
| JP5931323B2 JP5931323B2 (ja) | 2016-06-08 |
Family
ID=39111840
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009536282A Active JP5931323B2 (ja) | 2006-11-06 | 2007-11-06 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
| JP2013230872A Withdrawn JP2014043454A (ja) | 2006-11-06 | 2013-11-07 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
| JP2015208557A Pending JP2016014073A (ja) | 2006-11-06 | 2015-10-23 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013230872A Withdrawn JP2014043454A (ja) | 2006-11-06 | 2013-11-07 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
| JP2015208557A Pending JP2016014073A (ja) | 2006-11-06 | 2015-10-23 | 癌に対するベバシツマブと組み合わせたパクリタキセルおよびアルブミンのナノ粒子 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20070166388A1 (enExample) |
| EP (3) | EP3108885A1 (enExample) |
| JP (3) | JP5931323B2 (enExample) |
| KR (4) | KR20180012339A (enExample) |
| CN (2) | CN101573108A (enExample) |
| AU (1) | AU2007317859B2 (enExample) |
| BR (1) | BRPI0718528A2 (enExample) |
| CA (1) | CA2668607A1 (enExample) |
| CY (2) | CY1115271T1 (enExample) |
| DK (2) | DK2481405T3 (enExample) |
| ES (2) | ES2469716T3 (enExample) |
| HU (1) | HUE028472T2 (enExample) |
| IL (2) | IL198576A (enExample) |
| MX (1) | MX2009004803A (enExample) |
| NO (1) | NO343908B1 (enExample) |
| NZ (1) | NZ576856A (enExample) |
| PL (2) | PL2097078T3 (enExample) |
| PT (2) | PT2481405E (enExample) |
| RU (2) | RU2009121568A (enExample) |
| SI (2) | SI2097078T1 (enExample) |
| WO (1) | WO2008057562A1 (enExample) |
| ZA (1) | ZA200903132B (enExample) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030133955A1 (en) * | 1993-02-22 | 2003-07-17 | American Bioscience, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US20070122465A1 (en) * | 1993-02-22 | 2007-05-31 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US20070092563A1 (en) * | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| CN100462066C (zh) * | 1997-06-27 | 2009-02-18 | 美国生物科学有限公司 | 药剂的新制剂及其制备和应用方法 |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| SG166775A1 (en) | 2005-02-18 | 2010-12-29 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| HUE042678T2 (hu) | 2005-08-31 | 2019-07-29 | Abraxis Bioscience Llc | Vízben rosszul oldódó gyógyszerhatóanyagok és antimikrobiális szerek |
| US8034765B2 (en) * | 2005-08-31 | 2011-10-11 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| JP5590882B2 (ja) * | 2006-06-26 | 2014-09-17 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 化学療法増感剤としてのシステインに富む酸性分泌タンパク質（ｓｐａｒｃ） |
| US20080280987A1 (en) * | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| CA2679859A1 (en) * | 2006-11-01 | 2008-05-15 | George Mason Intellectual Properties, Inc. | Method for detecting and controlling cancer |
| JP5933893B2 (ja) | 2006-12-14 | 2016-06-15 | アブラクシス バイオサイエンス， エルエルシー | ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法 |
| CA3201293A1 (en) * | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US20100166869A1 (en) * | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| CN101677987A (zh) * | 2007-06-22 | 2010-03-24 | 赛多斯有限责任公司 | 不含吐温80的多西他赛的增溶制剂 |
| ITMI20080284A1 (it) * | 2008-02-22 | 2009-08-23 | Indena Spa | Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono |
| AU2009234127B2 (en) * | 2008-04-10 | 2015-04-30 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| EP2310006A4 (en) | 2008-07-03 | 2012-04-25 | Mayo Foundation | CANCER TREATMENT |
| EP2153821A1 (en) * | 2008-08-06 | 2010-02-17 | BioAlliance Pharma | Oral formulations of camptothecin derivatives |
| BRPI1007046B1 (pt) * | 2009-01-16 | 2019-07-16 | Rigel Pharmaceuticals, Inc. | Inibidores axl para uso em terapia de combinação para evitar, tratar ou controlar o câncer metastático. |
| WO2010105172A1 (en) * | 2009-03-13 | 2010-09-16 | Abraxis Bioscience, Llc | Combination therapy with thiocolchicine derivatives |
| ME03596B (me) | 2009-04-15 | 2020-07-20 | Abraxis Bioscience Llc | Kompozicije nanočesтica bez priona i postupci povezani sa njima |
| CN102573853A (zh) * | 2009-07-07 | 2012-07-11 | 诺尔姆奥克西斯公司 | 使用肌醇三焦磷酸减少多药抗性的方法 |
| US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
| US20110092579A1 (en) * | 2009-10-19 | 2011-04-21 | Scidose Llc | Solubilized formulation of docetaxel |
| US8541465B2 (en) * | 2009-10-19 | 2013-09-24 | Scidose, Llc | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid |
| US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
| AU2011221229B2 (en) * | 2010-02-23 | 2015-06-18 | F. Hoffmann-La Roche Ag | Anti-angiogenesis therapy for the treatment of ovarian cancer |
| HRP20160609T1 (hr) | 2010-03-26 | 2016-09-23 | Abraxis Bioscience, Llc | Postupci liječenja hepatocelularnog karcinoma |
| KR101894689B1 (ko) | 2010-03-29 | 2018-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
| CA2794147A1 (en) * | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
| EP2575804A4 (en) | 2010-06-04 | 2013-10-23 | Abraxis Bioscience Llc | METHOD FOR THE TREATMENT OF PANCREASCRE |
| NZ707377A (en) * | 2010-06-07 | 2015-09-25 | Abraxis Bioscience Llc | Combination therapy methods for treating proliferative diseases |
| US20120121510A1 (en) * | 2010-11-11 | 2012-05-17 | Brem Rachel F | Localized therapy following breast cancer surgery |
| US20130323265A1 (en) * | 2010-11-15 | 2013-12-05 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with dll4 antagonists |
| WO2012154861A2 (en) | 2011-05-09 | 2012-11-15 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| BR112014010417A2 (pt) | 2011-11-01 | 2014-11-18 | Celgene Corp | Métodos para o tratamento de cânceres com o uso de formulações orais de análogos de citidina |
| WO2013085902A1 (en) | 2011-12-05 | 2013-06-13 | The University Of Texas M.D. | Combination therapy methods for treating an inflammatory breast cancer |
| EP3560486A1 (en) | 2011-12-14 | 2019-10-30 | Abraxis BioScience, LLC | Use of polymeric excipients for lyophilization or freezing of particles |
| MX365139B (es) * | 2012-03-13 | 2019-05-24 | Hoffmann La Roche | Uso de una terapia combinada de bevacizumab y paclitaxel en el tratamiento de cáncer de ovario epitelial resistente al platino, carcinoma de las trompas de falopio resistente al platino, o carcinoma peritoneal primario resistente al platino. |
| EP2903610B1 (en) | 2012-10-01 | 2021-11-03 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| EP2953622B1 (en) * | 2013-02-11 | 2021-03-24 | Abraxis BioScience, LLC | Methods of treating melanoma |
| CA2903454A1 (en) | 2013-03-12 | 2014-10-02 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
| EP2968191B1 (en) | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| US10842969B2 (en) | 2013-10-25 | 2020-11-24 | Mercator Medsystems, Inc. | Systems and methods of treating malacia by local delivery of hydrogel to augment tissue |
| WO2015134543A1 (en) * | 2014-03-05 | 2015-09-11 | Sorrento Therapeutics, Inc. | Pharmacokinetically equivalent nanoparticle compositions |
| EP2924022A1 (en) * | 2014-03-27 | 2015-09-30 | INDENA S.p.A. | Amorphous form of a thiocolchicine derivative |
| CA2950926A1 (en) | 2014-06-13 | 2015-12-17 | Mayo Foundation For Medical Education And Research | Albumin-bound paclitaxel nanoparticle/rituximab complexes for treatment of cd20-expressing lymphomas |
| WO2015195476A1 (en) | 2014-06-16 | 2015-12-23 | Mayo Foundation For Medical Education And Research | Treating myelomas |
| WO2015195634A1 (en) | 2014-06-17 | 2015-12-23 | Celgne Corporation | Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine |
| WO2015018380A2 (en) * | 2014-07-03 | 2015-02-12 | Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. | Therapeutic nanoparticles and the preparation methods thereof |
| ES2763318T3 (es) * | 2014-10-06 | 2020-05-28 | Mayo Found Medical Education & Res | Composiciones de vehículo-anticuerpo y procedimientos para preparar y usar las mismas |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| EA036790B1 (ru) | 2015-06-29 | 2020-12-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способ лечения злокачественной пекомы |
| WO2017176265A1 (en) * | 2016-04-06 | 2017-10-12 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| WO2017031368A1 (en) * | 2015-08-18 | 2017-02-23 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| CN105288639A (zh) * | 2015-11-23 | 2016-02-03 | 中国药科大学 | 一种载阿霉素的主动靶向白蛋白纳米载体的制备及其应用 |
| US11571469B2 (en) | 2016-01-07 | 2023-02-07 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression |
| EP3413874A4 (en) | 2016-02-12 | 2020-01-22 | Mayo Foundation for Medical Education and Research | TREATMENTS FOR BLOOD CANCER |
| EP3432928A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC |
| AU2017238119A1 (en) | 2016-03-21 | 2018-10-11 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| RU2019105550A (ru) * | 2016-08-05 | 2020-09-07 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Модифицированные комплексы с наночастицами антитело-альбумин для лечения злокачественного новообразования |
| JP6956091B2 (ja) * | 2016-08-26 | 2021-10-27 | 哲治 奥野 | 微小ナノ化薬剤およびその利用 |
| MX2019002474A (es) | 2016-09-01 | 2019-09-18 | Mayo Found Medical Education & Res | Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres. |
| JP2019526579A (ja) | 2016-09-01 | 2019-09-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ | Ｔ細胞癌を標的とする為の方法及び組成物 |
| CN109890422A (zh) | 2016-09-06 | 2019-06-14 | 梅约医学教育与研究基金会 | 紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法 |
| RU2019110071A (ru) | 2016-09-06 | 2020-10-08 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Способы лечения злокачественных новообразований, экспрессирующих pd-l1 |
| WO2018048815A1 (en) | 2016-09-06 | 2018-03-15 | Nantibodyfc, Llc | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| CN106310291A (zh) * | 2016-09-14 | 2017-01-11 | 东南大学 | 主动靶向抗肿瘤纳米药物及其制备方法和应用 |
| AU2017347853B2 (en) | 2016-10-27 | 2022-02-17 | Celgene Quanticel Research, Inc. | Bromodomain and extra-terminal protein inhibitor combination therapy |
| EP3532077A4 (en) * | 2016-10-28 | 2020-06-10 | Nant Holdings IP, LLC | Avatar dendritic cells: the neoantigen natural killer t-cell chemo immuno radiation composition inducing immunogenic cell death |
| WO2019090272A1 (en) | 2017-11-06 | 2019-05-09 | Flx Bio, Inc. | Chemokine receptor modulators for treatment of epstein barr virus positive cancer |
| WO2019104042A1 (en) * | 2017-11-21 | 2019-05-31 | University Of Iowa Research Foundation | Synthetically lethal nanoparticles for treatment of cancers |
| US20190184031A1 (en) * | 2017-12-19 | 2019-06-20 | Abraxis Bioscience, Llc | Methods of treating colon cancer using nanoparticle mtor inhibitor combination therapy |
| US11524053B2 (en) | 2018-01-26 | 2022-12-13 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
| EP3768268A4 (en) | 2018-03-20 | 2022-02-23 | Abraxis BioScience, LLC | METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE |
| EP4051241A4 (en) | 2019-10-28 | 2023-12-06 | Abraxis BioScience, LLC | PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN |
| IL293131A (en) | 2019-11-25 | 2022-07-01 | Univ California | Long-acting vegf inhibitors for intraocular neovascularization |
| KR102263606B1 (ko) | 2020-02-11 | 2021-06-10 | 충북대학교 산학협력단 | 파클리탁셀과 알피늄이소플라본을 함유한 나노 마이셀, 이의 제조방법 및 이의 용도 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5470571A (en) | 1988-01-27 | 1995-11-28 | The Wistar Institute | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 |
| IL98528A0 (en) | 1990-06-21 | 1992-07-15 | Merck & Co Inc | Pharmaceutical compositions containing hybrid for killing bladder cancer cells |
| DK0531472T3 (da) | 1991-03-06 | 2003-12-01 | Merck Patent Gmbh | Humaniserede monoklonale antistoffer |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| CA2192470A1 (en) | 1994-01-14 | 1995-07-20 | Paul A. Brown | Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf |
| ES2236634T3 (es) | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| DK1071440T3 (da) | 1998-04-16 | 2007-05-14 | Eurovita As | Nye synergistiske sammensætninger indeholdende aromatiske forbindelser og i Alpinia galanga tilstedeværende terpenoider |
| AU777528B2 (en) | 1999-04-22 | 2004-10-21 | Abraxis Bioscience, Llc | Long term administration of pharmacologically active agents |
| ITMI20001107A1 (it) * | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| US20040143004A1 (en) | 2002-02-26 | 2004-07-22 | Joseph Fargnoli | Metronomic dosing of taxanes |
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| AR046510A1 (es) * | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| MXPA06003163A (es) * | 2003-09-23 | 2006-06-05 | Novartis Ag | Combinacion de un inhibidor de receptor de vegf con un agente quimioterapeutico. |
| US20060003931A1 (en) | 2004-05-06 | 2006-01-05 | Genentech, Inc. | Crystal structure of the hepatocyte growth factor and methods of use |
| MXPA06014065A (es) | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
| EP1753455A2 (en) | 2004-06-04 | 2007-02-21 | Genentech, Inc. | Method for treating multiple sclerosis |
| SV2006002143A (es) | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
| US8772269B2 (en) * | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
| KR101345002B1 (ko) * | 2005-01-21 | 2013-12-31 | 아스텍스 테라퓨틱스 리미티드 | 제약 화합물 |
| SG166775A1 (en) * | 2005-02-18 | 2010-12-29 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| EP1862179A4 (en) * | 2005-02-28 | 2010-12-15 | Eisai R&D Man Co Ltd | NOVEL USE OF A SULFONAMIDE COMPOUND IN COMBINATION WITH AN ANGIOGENESIS INHIBITOR |
| HUE042678T2 (hu) * | 2005-08-31 | 2019-07-29 | Abraxis Bioscience Llc | Vízben rosszul oldódó gyógyszerhatóanyagok és antimikrobiális szerek |
| US8034765B2 (en) * | 2005-08-31 | 2011-10-11 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
-
2006
- 2006-11-06 US US11/594,417 patent/US20070166388A1/en not_active Abandoned
-
2007
- 2007-11-06 CA CA002668607A patent/CA2668607A1/en not_active Abandoned
- 2007-11-06 BR BRPI0718528-6A patent/BRPI0718528A2/pt not_active Application Discontinuation
- 2007-11-06 ES ES07839976.3T patent/ES2469716T3/es active Active
- 2007-11-06 MX MX2009004803A patent/MX2009004803A/es active IP Right Grant
- 2007-11-06 RU RU2009121568/15A patent/RU2009121568A/ru unknown
- 2007-11-06 PL PL07839976T patent/PL2097078T3/pl unknown
- 2007-11-06 PT PT121549950T patent/PT2481405E/pt unknown
- 2007-11-06 ZA ZA200903132A patent/ZA200903132B/xx unknown
- 2007-11-06 EP EP16161396.3A patent/EP3108885A1/en not_active Withdrawn
- 2007-11-06 HU HUE12154995A patent/HUE028472T2/en unknown
- 2007-11-06 NZ NZ576856A patent/NZ576856A/en not_active Application Discontinuation
- 2007-11-06 EP EP07839976.3A patent/EP2097078B1/en active Active
- 2007-11-06 CN CNA2007800490545A patent/CN101573108A/zh active Pending
- 2007-11-06 SI SI200731475T patent/SI2097078T1/sl unknown
- 2007-11-06 DK DK12154995.0T patent/DK2481405T3/en active
- 2007-11-06 KR KR1020187002044A patent/KR20180012339A/ko not_active Withdrawn
- 2007-11-06 PT PT78399763T patent/PT2097078E/pt unknown
- 2007-11-06 EP EP12154995.0A patent/EP2481405B1/en active Active
- 2007-11-06 CN CN201510264733.0A patent/CN104940929A/zh active Pending
- 2007-11-06 KR KR1020097011640A patent/KR20090087906A/ko not_active Ceased
- 2007-11-06 PL PL12154995.0T patent/PL2481405T3/pl unknown
- 2007-11-06 KR KR1020157014446A patent/KR20150065957A/ko not_active Ceased
- 2007-11-06 JP JP2009536282A patent/JP5931323B2/ja active Active
- 2007-11-06 SI SI200731795A patent/SI2481405T1/sl unknown
- 2007-11-06 KR KR1020177002657A patent/KR101857142B1/ko active Active
- 2007-11-06 WO PCT/US2007/023446 patent/WO2008057562A1/en not_active Ceased
- 2007-11-06 ES ES12154995.0T patent/ES2576289T3/es active Active
- 2007-11-06 DK DK07839976.3T patent/DK2097078T3/da active
- 2007-11-06 AU AU2007317859A patent/AU2007317859B2/en active Active
-
2009
- 2009-05-05 IL IL198576A patent/IL198576A/en active IP Right Grant
- 2009-06-05 NO NO20092179A patent/NO343908B1/no unknown
-
2013
- 2013-11-05 RU RU2013149282A patent/RU2673805C2/ru active
- 2013-11-07 JP JP2013230872A patent/JP2014043454A/ja not_active Withdrawn
-
2014
- 2014-06-26 CY CY20141100462T patent/CY1115271T1/el unknown
-
2015
- 2015-10-23 JP JP2015208557A patent/JP2016014073A/ja active Pending
-
2016
- 2016-03-02 IL IL244390A patent/IL244390A/en active IP Right Grant
- 2016-06-17 CY CY20161100552T patent/CY1117725T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509331A5 (enExample) | ||
| RU2009121568A (ru) | Комбинации и способы введения терапевтических агентов и комбинированная терапия | |
| JP2010529025A5 (enExample) | ||
| Agnello et al. | Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors | |
| Yan et al. | Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid–polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo | |
| JP2016506908A5 (enExample) | ||
| JP2012520323A5 (enExample) | ||
| JP2013527232A5 (enExample) | ||
| JP2013523656A5 (enExample) | ||
| JP2013527233A5 (enExample) | ||
| US12391944B2 (en) | Magnetic inorganic iron-based nanoparticles | |
| JP2017025090A5 (enExample) | ||
| JP2016513075A5 (enExample) | ||
| JP2016505018A5 (enExample) | ||
| JP2014531456A5 (enExample) | ||
| RU2012157805A (ru) | Способы лечения рака мочевого пузыря | |
| JP2016513657A5 (enExample) | ||
| CA3024135C (en) | Compositions intended for the administration of RNA in the form of nanoparticles and associated method of use | |
| Erdoğar et al. | Therapeutic efficacy of folate receptor-targeted amphiphilic cyclodextrin nanoparticles as a novel vehicle for paclitaxel delivery in breast cancer | |
| HRP20160609T1 (hr) | Postupci liječenja hepatocelularnog karcinoma | |
| JP2012158602A5 (enExample) | ||
| JP2010523696A5 (enExample) | ||
| JP2015517529A5 (enExample) | ||
| JP2017514800A5 (enExample) | ||
| JP2016515628A5 (enExample) |